NSCLC - First-Line-Chemotherapie Häufiger Als Erwartet

Pneumologie - Germany
doi 10.1055/s-0033-1343060
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Georg Thieme Verlag KG

Related search

Chemotherapie Als Alternative Zur Bestrahlung Bei Niedriggradigem Gliom

Im Focus Onkologie
2012English

Arthrose Von Hüfte Und Knie: Neuropathische Schmerzen Häufiger Als Gedacht

Aktuelle Rheumatologie
Rheumatology
2018English

Respiratorische Insuffizienz Und Pulmonale Fibrose Als Spätfolge Einer Chemotherapie - Induziert Durch Sauerstoffexposition

Pneumologie
MedicinePulmonaryRespiratory Medicine
2005English

Osimertinib as First-Line Therapy in Advanced NSCLC: A Profile of Its Use

Drugs and Therapy Perspectives
Pharmacology
2018English

CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC

Clinical Cancer Research
Cancer ResearchOncology
2013English

Cost-Effectiveness of First-Line Therapy for Advanced Non-Small Cell Lung Cancer (Nsclc)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Clinical Observation of Gefitinib as a First-Line Therapy in Sixty-Eight Patients With Advanced NSCLC

Oncology Letters
Cancer ResearchOncology
2012English

P3.04-02 Early Plasma ctDNA Response Anticipates Clinical Response to First-Line Immunotherapy in Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

First-Line Osimertinib in Patients With Treatment-Naive Somatic or Germline EGFR T790M–Mutant Metastatic NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy